Background: Neuropathologically, Alzheimer’s disease (AD) is characterized by accumulation of a 42 amino acid peptide called amyloid-β (Aβ42) in extracellular senile plaques together with intraneuronal inclusions of hyperphosphorylated tau protein in neurofibrillary tangles and neuronal degeneration. These changes are reflected in the cerebrospinal fluid (CSF), the volumes and production rates of which vary considerably between individuals, by reduced concentration of Aβ42, increased concentration of phosphorylated tau (P-tau) protein, and increased concentration of total tau (T-tau) protein, respectively.
Objective: To examine the outstanding question if CSF concentrations of AD associated biomarkers are influenced by variations in CSF volumes, CSF production rate, and intracranial pressure in healthy individuals.
Methods: CSF concentrations of Aβ42, P-tau, and T-tau, as well as a number of other AD-related CSF biomarkers were analyzed together with intracranial subarachnoid, ventricular, and spinal CSF volumes, as assessed by magnetic resonance imaging volumetric measurements, and CSF production rate in 19 cognitively normal healthy subjects (mean age 70.6, SD 3.6 years).
Results: Negative correlations were seen between the concentrations of three CSF biomarkers (albumin ratio, Aβ38, and Aβ40), and ventricular CSF volume, but apart from this finding, no significant correlations were observed.
Conclusion: These results speak against inter-individual variations in CSF volume and production rate as important confounds in the AD biomarker research field.
BlennowK, de LeonMJ, ZetterbergH (2006) Alzheimer’s disease. Lancet368, 387–403.
2.
BlennowK, DuboisB, FaganAM, LewczukP, de LeonMJ, HampelH (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement11, 58–69.
3.
HulstaertF, BlennowK, IvanoiuA, SchoonderwaldtHC, RiemenschneiderM, De DeynPP, BancherC, CrasP, WiltfangJ, MehtaPD, IqbalK, PottelH, VanmechelenE, VandersticheleH (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology52, 1555–1562.
4.
NaggaK, GottfriesJ, BlennowK, MarcussonJ (2002) Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord14, 183–190.
5.
MollenhauerB, CepekL, BiblM, WiltfangJ, Schulz-SchaefferWJ, CiesielczykB, NeumannM, SteinackerP, KretzschmarHA, PoserS, TrenkwalderC, OttoM (2005) Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord19, 164–170.
6.
GrossmanM, FarmerJ, LeightS, WorkM, MooreP, Van DeerlinV, PraticoD, ClarkCM, CoslettHB, ChatterjeeA, GeeJ, TrojanowskiJQ, LeeVM (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol57, 721–729.
7.
MoriyaM, MiyajimaM, NakajimaM, OginoI, AraiH (2015) Impact of cerebrospinal fluid shunting for idiopathic normal pressure hydrocephalus on the amyloid cascade. PLoS One10, e0119973.
8.
JeppssonA, HölttaM, ZetterbergH, BlennowK, WikkelsøC, TullbergM (2016) Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS13, 13.
9.
HampelH, BurgerK, PruessnerJC, ZinkowskiR, DeBernardisJ, KerkmanD, LeinsingerG, EvansAC, DaviesP, MollerHJ, TeipelSJ (2005) Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol62, 770–773.
10.
TapiolaT, AlafuzoffI, HerukkaSK, ParkkinenL, HartikainenP, SoininenH, PirttilaT (2009) Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol66, 382–389.
11.
MufsonEJ, IkonomovicMD, CountsSE, PerezSE, Malek-AhmadiM, ScheffSW, GinsbergSD (2016) Molecular and cellular pathophysiology of preclinical Alzheimer’s disease. Behav Brain Res311, 54–69.
12.
RosenC, HanssonO, BlennowK, ZetterbergH (2013) Fluid biomarkers in Alzheimer’s disease - current concepts. Mol Neurodegener8, 20.
13.
NalivaevaNN, TurnerAJ (2013) The amyloid precursor protein: A biochemical enigma in brain develoment, function and disease. FEBS Lett587, 2046–2054.
14.
JarrettJT, BergerEP, LansburyPTJr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer’s disease. Biochemistry32, 4693–4697.
15.
MastersCL, SimmsG, WeinmanNA, MulthaupG, McDonaldBL, BeyreutherK (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A82, 4245–4249.
16.
QiuT, LiuQ, ChenYX, ZhaoYF, LiYM (2015) Abeta42 and Abeta40: Similarities and differences. J Pept Sci21, 522–529.
17.
AlbertMS, DekoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
18.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
19.
DuboisB, FeldmanHH, JacovaC, CummingsJL, DekoskyST, Barberger-GateauP, DelacourteA, FrisoniG, FoxNC, GalaskoD, GauthierS, HampelH, JichaGA, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SarazinM, deSouza LC, SternY, VisserPJ, ScheltensP (2010) Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol9, 1118–1127.
20.
DuboisB, FeldmanHH, JacovaC, DekoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol6, 734–746.
21.
BlennowK, HampelH, WeinerM, ZetterbergH (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol6, 131–144.
de LeonMJ, DeSantiS, ZinkowskiR, MehtaPD, PraticoD, SegalS, ClarkC, KerkmanD, DeBernardisJ, LiJ, LairL, ReisbergB, TsuiW, RusinekH (2004) MRI and CSF studies in the early diagnosis of Alzheimer’s disease. J Intern Med256, 205–223.
24.
SilverbergGD, HeitG, HuhnS, JaffeRA, ChangSD, Bronte-StewartH, RubensteinE, PossinK, SaulTA (2001) The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer’s type. Neurology57, 1763–1766.
25.
EdsbaggeM, TisellM, JacobssonL, WikkelsoC (2004) Spinal CSF absorption in healthy individuals. Am J Physiol Regul Integr Comp Physiol287, R1450–R1455.
AmbarkiK, LindqvistT, WahlinA, PettersonE, WarntjesMJ, BirganderR, MalmJ, EklundA (2011) Evaluation of automatic measurement of the intracranial volume based on quantitative MR imaging. AJNR Am J Neuroradiol33, 1951–1956.
TibblingG, LinkH, OhmanS (1977) Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest37, 385–390.
35.
FarrallAJ, WardlawJM (2009) Blood-brain barrier: Ageing and microvascular disease–systematic review and meta-analysis. Neurobiol Aging30, 337–352.
36.
HodelJ, LebretA, PetitE, LeclercX, ZinsM, VignaudA, DecqP, RahmouniA (2013) Imaging of the entire cerebrospinal fluid volume with a multistation 3D SPACE MR sequence: Feasibility study in patients with hydrocephalus. Eur Radiol23, 1450–1458.
37.
LehmannM, DouiriA, KimLG, ModatM, ChanD, OurselinS, BarnesJ, FoxNC (2010) Atrophy patterns in Alzheimer’s disease and semantic dementia: A comparison of FreeSurfer and manual volumetric measurements. Neuroimage49, 2264–2274.
38.
NestorSM, RupsinghR, BorrieM, SmithM, AccomazziV, WellsJL, FogartyJ, BarthaR, Alzheimer’s Disease Neuroimaging Initiative (2008) Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain131(Pt 9), 2443–2454.
